Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis
Latest Information Update: 29 Mar 2024
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms PANIRINOX; UCGI28_PANIRINOX
- 24 Oct 2023 First results (n=92) presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to an Amgen media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.
- 30 Aug 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.